There are currently 998 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657
Recruiting
The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in com... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center - McKinley Drive, Tampa, Florida
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
NCT06305676
Recruiting
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Oropharyngeal Cancer, HPV-Related Carcinoma
Register for Updates
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
NCT06109467
Recruiting
The purpose of the study is to test the effects, both good and bad, of the research study drug Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX chemotherapy. This study will also look at the safety of Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX in HER2 overexpressing Gastroesophageal cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: GastroEsophageal Cancer, Gastric Cancer
Register for Updates
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299
Recruiting
The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard of care treatment in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on a stable standard of care regimen for ≥ 6 months prior to screening. The standard of care includes 2 or 3 medicines, antiretroviral agents (ARVs). The primary objective of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: BayCare Health System, Inc./St. Joseph's Hospital, Tampa, Florida
Conditions: HIV-1-Infection
Register for Updates
REFLECT: Reproductive Education and Fertility Links for Cancer Treatment
NCT06199726
Recruiting
The purpose of this study is to evaluate a web-based education tool geared at helping Adolescent and Young Adult (AYA) patients better understand fertility and genetic risks for cancer in future offspring.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Reproductive Behavior
Register for Updates
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
NCT06337552
Recruiting
The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer (NSCLC) patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiation and NSCLC patients receiving immunotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Rectal Cancer, Non-Small Cell Lung Cancer
Register for Updates
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05535166
Recruiting
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/16/2025
Locations: St. Joseph's Children's Hospital, Tampa, Florida
Conditions: Medulloblastoma
Register for Updates
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
NCT05704361
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Multiple Sclerosis
Register for Updates
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Tampa, Florida, Tampa, Florida
Conditions: Alopecia Areata
Register for Updates
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06144606
Recruiting
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Register for Updates
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
NCT06553872
Recruiting
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Mantle Cell Lymphoma
Register for Updates
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
NCT05675059
Recruiting
The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are receiving chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates